Straits Times Index
3,204.82 +2.01 (+0.06%) Nikkei
32,402.41 -168.62 (-0.52%) Hang Seng
18,057.45 +402.04 (+2.28%) FTSE 100
7,683.91 +5.29 (+0.07%) Bitcoin USD
26,560.46 +4.15 (+0.02%) CMC Crypto 200
565.87 -2.18 (-0.38%)
ABIONYX Pharma SA (0RAG.L)
| Previous close | 1.2000 |
| Open | 1.1500 |
| Bid | 0.0000 x N/A |
| Ask | 0.0000 x N/A |
| Day's range | 1.1500 - 1.1500 |
| 52-week range | 1.1500 - 2.3600 |
| Volume | |
| Avg. volume | 2,985 |
| Market cap | 253,561 |
| Beta (5Y monthly) | 0.29 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.1480 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
Business WireABIONYX Pharma: Monthly statement of total voting rights and shares forming the company’s share capital
PARIS, September 19, 2023--Regulatory News: ABIONYX Pharma (Paris:ABNX):
Business WireWorld Sepsis Day September 13, 2023: ABIONYX Pharma Confirms Its Commitment to Sepsis, a Global Public Health Issue
TOULOUSE, France & LAKELAND, Mich., September 12, 2023--Regulatory News: ABIONYX Pharma, (FR0012616852 - ABNX - PEA PME eligible), a new generation biotech company dedicated to the discovery and development of innovative therapies based on the world's only natural recombinant apoA-1, reports on its commitment and strategic analysis for the development of its innovative breakthrough treatment on World Sepsis Day.
Business WireABIONYX Pharma Provides an Update on Its Business and Cash Position for the First Half of 2023
TOULOUSE, France & LAKELAND, Mich., August 17, 2023--Regulatory News: ABIONYX Pharma, (FR0012616852 - ABNX - PEA PME eligible), a new generation biotech company dedicated to the discovery and development of innovative therapies based on the world's only natural recombinant ApoA-I, today provided an update on its business and cash position for the 1st half to June 30, 2023.
